Evidence map›Paper›PMID 27604872›Full record

ArticleNucleic acids research2016

A quantitative proteomics approach identifies ETV6 and IKZF1 as new regulators of an ERG-driven transcriptional network.

Ashwin Unnikrishnan, Yi F Guan, Yizhou Huang, Dominik Beck, Julie A I Thoms, Sofie Peirs, Kathy Knezevic, Shiyong Ma, Inge V de Walle, Ineke de Jong and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Novel single-cell technologies in acute myeloid leukemia research.Translational research : the journal of laboratory and clinical medicine · 2017
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Ashwin UnnikrishnanAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia Ashwin.unnikrishnan@unsw.edu.au.
Yi F GuanAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Yizhou HuangAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Dominik BeckAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Julie A I ThomsAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Sofie PeirsCentre for Health Technologies and the School of Software, University of Technology, Sydney, 2007, Australia.
Kathy KnezevicAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Shiyong MaAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia.
Inge V de WalleDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185 9000 Ghent, Belgium.
Ineke de JongDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, SE-221 00, Lund, Sweden.
Zara AliChildren's Cancer Institute Australia, Sydney, New South Wales, 2052 Australia.
Ling ZhongBioanalytical Mass Spectrometry Facility, The University of New South Wales, Sydney, New South Wales 2052, Australia.
Mark J RafteryBioanalytical Mass Spectrometry Facility, The University of New South Wales, Sydney, New South Wales 2052, Australia.
Tom TaghonDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University, De Pintelaan 185 9000 Ghent, Belgium.
Jonas LarssonDivision of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, SE-221 00, Lund, Sweden.
Karen L MacKenzieChildren's Cancer Institute Australia, Sydney, New South Wales, 2052 Australia.
Pieter Van VlierbergheCentre for Health Technologies and the School of Software, University of Technology, Sydney, 2007, Australia.
Jason W H WongAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia Jason.wong@unsw.edu.au.
John E PimandaAdult Cancer Program, Prince of Wales Clinical School, Lowy Cancer Research Centre, University of New South Wales, Sydney, 2052, Australia jpimanda@unsw.edu.au.
UNSW Sydney · AUGhent University Hospital · BEChildren's Cancer Institute Australia · AULund University · SEUniversity of Technology Sydney · AUPrince of Wales Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant stem cell-like gene regulatory networks are a feature of leukaemogenesis. The ETS-related gene (ERG), an important regulator of normal haematopoiesis, is also highly expressed in T-ALL and acute myeloid leukaemia (AML). However, the transcriptional regulation of ERG in leukaemic cells remains poorly understood. In order to discover transcriptional regulators of ERG, we employed a quantitative mass spectrometry-based method to identify factors binding the 321 bp ERG +85 stem cell enhancer region in MOLT-4 T-ALL and KG-1 AML cells. Using this approach, we identified a number of known binders of the +85 enhancer in leukaemic cells along with previously unknown binders, including ETV6 and IKZF1. We confirmed that ETV6 and IKZF1 were also bound at the +85 enhancer in both leukaemic cells and in healthy human CD34

Indexed as

Transcription, GeneticBase SequenceBinding SitesCell Line, TumorConsensus SequenceEnhancer Elements, GeneticETS Translocation Variant 6 ProteinGene Expression Regulation, LeukemicGene Regulatory NetworksHumansIkaros Transcription FactorKaplan-Meier EstimateLeukemia, Myeloid, AcutePrognosisProportional Hazards ModelsProtein BindingERG protein, humanETS Translocation Variant 6 ProteinIkaros Transcription FactorIKZF1 protein, humanProteomeProto-Oncogene Proteins c-etsRepressor ProteinsTranscriptional Regulator ERG

Identifiers

PMID27604872
PMCPMC5159545
OpenAlexW2518414681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.